“My hope is that this campaign will greatly increase awareness of sarcoidosis and encourage Black patients to participate in clinical trials. That will ultimately improve our lives and benefit everyone in the sarcoidosis community.” Calvin Harris FSR Patient...
FSR is proud to announce the launch of the Ignore No More: ACTe Now! (Advance Clinical Trials for Equity in Sarcoidosis) campaign. The goals of this campaign are to increase representation of Black American sarcoidosis patients in clinical trials, raise awareness of...
FSR is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2022-2024 is being awarded to Dr. Nancy Lin from National Jewish Health, a Founding Member of the FSR Global Sarcoidosis Clinic Alliance, for her project, “Defining MicroRNA Biomarkers...
On April 21, 2022, The Foundation for Sarcoidosis Research (FSR) hosted a virtual Patient Listening Session on Pulmonary Sarcoidosis with the US Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-regulatory, non-public...
FSR is pleased to announce the appointment of Michael Klingher to the FSR Board of Directors. Klingher has over 35 years’ experience as an investment banker and investor in commercial real estate, working with Goldman Sachs and in managing his own real estate...
Foundation for Sarcoidosis Research (FSR) announces the launch of the FSR Global Sarcoidosis Clinic Alliance, a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving the lives of those with sarcoidosis through...
SUNY Upstate Medical University Auyon Ghosh MD, MPH, to be presented with $50,000 Partnership Research Grant from American Thoracic Society and Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit...
In September 2021, an article entitled “Challenges of Sarcoidosis and Its Management” (Drent et al., 2021) was published in the prestigious New England Journal of Medicine. This article, written by two active members on FSR’s Scientific Advisory Board, Marjolein...
The Foundation for Sarcoidosis Research (FSR)’s team is growing to better support the needs identified by the sarcoidosis community! FSR is pleased to announce that Diane Driscoll joined the FSR team as Global Head of Clinical Engagement effective February 1, 2022. ...
Act Now to Protect Drug Development. As part of the budgeting process, Congress is discussing cutting back the Orphan Drug Tax Credit for pharmaceutical companies. Most of the drugs in sarcoidosis are not FDA-approved for sarcoidosis, but are repurposed from...
